Company overview
Research-based global biopharmaceutical company (Pfizer Inc.)
Source evidence
“Pfizer Inc. is a research-based, global biopharmaceutical company.”

PFE
Updated: 05/11/2026, 00:14:06
No historical data available
Pfizer Inc. is a global biopharmaceutical leader engaged in the research, development, production, marketing, and distribution of a wide array of medicinal and vaccine products worldwide. Its comprehensive portfolio addresses diverse therapeutic areas, including cardiovascular health and women's health, featuring key brands such as the Premarin family and Eliquis. The company also offers advanced biologics, small molecule drugs, immunotherapies, and biosimilars for various conditions, exemplified by Ibrance, Xtandi, and Retacrit. Furthermore, Pfizer provides sterile injectables, anti-infective agents, and a significant oral treatment for COVID-19, including Paxlovid. A substantial portion of its offerings comprises vaccines for infectious diseases such as pneumococcal and meningococcal disease, tick-borne encephalitis, and COVID-19, with notable products like Comirnaty and the Prevnar family. The firm also develops biosimilars for chronic autoimmune and inflammatory disorders, including Inflectra and Xeljanz, alongside specialized therapies for rare conditions like amyloidosis, hemophilia, and endocrine disorders, under brands such as Vyndaqel and BeneFIX. Beyond its proprietary products, Pfizer operates a contract manufacturing division. Its extensive customer base includes wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual medical practices, and public health organizations. The company actively fosters strategic collaborations with numerous partners, such as Bristol-Myers Squibb Company, BioNTech SE, and Merck KGaA. Established in 1849, Pfizer Inc. is headquartered in New York, New York.
No summaries found.
Reported and calculated KPIs plus operational exposure disclosed in the FY 2025 filing.
Revenue
N/A
FY — · Reported
Net income
$7.8B
FY 2025 · Reported
Gross margin
N/A
FY — · Reported
Free cash flow
$9.1B
FY 2025 · Calculated
R&D intensity
N/A
FY — · Reported
Share repurchases
N/A
FY — · Reported
| Product / service | Sales | Share of sales | YoY growth | By reported area |
|---|---|---|---|---|
products_over_1b_usdSource evidence“We recorded revenues of more than $1 billion for each of 12 products that collectively accounted for 65% of Total revenues in 2025. For example, Eliquis accounted for 13% of Total revenues in 2025.” | 12 | N/A | N/A | Not disclosed by product and area |
Other offerings mentioned without separate sales
Area-level product sales are displayed only when the filing reports a product × geography breakdown. Regional totals are not allocated across products by estimation.
Map layer
Pins show disclosed operations. The heatmap colors the filing’s reported geographies; regional figures shade the region and are not estimates for each country.
Only locations and quantities explicitly supported by the filing are displayed. A country-level manufacturing percentage or product allocation is shown only when the source discloses it; materiality scores are never presented as production shares.
Company overview
Research-based global biopharmaceutical company (Pfizer Inc.)
“Pfizer Inc. is a research-based, global biopharmaceutical company.”
Company overview
Research-based global biopharmaceutical company (incorporated Delaware, June 2, 1942)
“Pfizer Inc. is a research-based, global biopharmaceutical company.”
Operating segments 2025
Three operating segments in 2025: Biopharma (only reportable), PC1, Pfizer Ignite; new Global Hospital and Biosimilars organization effective Jan 1, 2026
“In 2025, we managed our commercial operations through a global structure consisting of three operating segments: Biopharma, PC1 and Pfizer Ignite. Biopharma was the only reportable segment.”
Operating segments
Three operating segments: Biopharma (only reportable segment), PC1 (CDMO/specialty API supplier), Pfizer Ignite (being wound down)
“We manage our commercial operations through a global structure consisting of three operating segments, each led by a single manager: Biopharma, PC1 and Pfizer Ignite.”
Restructuring cost drivers across functions
Cost-reduction/productivity initiatives involve site closings, workforce reductions, shared services expansion and digital enablement, impacting sales/marketing, manufacturing, R&D and corporate enabling functions.
“we typically incur costs and charges for site closings and other facility rationalization actions, workforce reductions and the expansion of shared services, including the development of global systems, and digital enablement”
Key disclosed products
Comirnaty, Paxlovid, Vyndaqel family, Eliquis, Padcev, Lorbrena, Abrysvo, Enbrel, oncology biosimilars
“The operational decrease was primarily driven by declines in COVID-19 product revenues, partially offset by increases from the Vyndaqel family, Eliquis, Padcev, Lorbrena, Abrysvo and Oncology biosimilars.”
Oncology portfolio
Innovative oncology portfolio of ADCs, small molecules, bispecifics and immunotherapies (Ibrance, Xtandi, Padcev, Adcetris, etc.)
“Innovative oncology product portfolio of ADCs, small molecules, bispecifics and other immunotherapies that treat a wide range of cancers”
Specialty Care portfolio
Inflammation & immunology, rare disease (amyloidosis, hemophilia, endocrine), anti-infective and immunoglobulin medicines
“Rare disease product portfolio for a number of therapeutic areas with rare diseases, including amyloidosis, hemophilia and endocrine diseases – select products include: the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla and Hympavzi.”
Primary Care portfolio
Internal medicine (Eliquis), migraine (Nurtec ODT/Vydura, Zavzpret), vaccines (Prevnar family, Comirnaty, Abrysvo, FSME/IMMUN-TicoVac, Nimenrix, Trumenba), COVID-19 treatment (Paxlovid)
“Vaccines product portfolio across all ages – select products include: the Prevnar family, Comirnaty, Abrysvo, FSME/IMMUN-TicoVac, Nimenrix and Trumenba.”
Hospital and Biosimilars portfolio
Off-patent branded and generic sterile injectables and biosimilars (new Global Hospital and Biosimilars organization effective January 1, 2026)
“at the beginning of 2026, we made changes in our commercial structure, which included the transition of certain off-patent branded and generic sterile injectables and biosimilars... to a new Global Hospital and Biosimilars organization”
2025 revenue drivers
Revenues decreased $1.0B (2%) to $62.6B, driven by COVID-19 declines; excluding Comirnaty and Paxlovid, revenues +6% operationally
“Excluding contributions from Comirnaty and Paxlovid, Total revenues increased 6% operationally.”
Product concentration — 12 products >$1B, 65% of revenue
12 products each >$1B accounted for 65% of Total revenues in 2025; Eliquis alone 13%
“We recorded revenues of more than $1 billion for each of 12 products that collectively accounted for 65% of Total revenues in 2025. For example, Eliquis accounted for 13% of Total revenues in 2025.”
Raw materials sourcing
Raw materials procured worldwide from numerous suppliers; no significant 2026 availability impact anticipated but supply chain risks monitored
“We do not anticipate the availability of raw materials to have a significant impact on our operations in 2026, but are monitoring potential supply chain disruptions as a result of ongoing geopolitical and trade negotiations”
Metsera acquisition (obesity)
Acquired Metsera in November 2025 (obesity/cardiometabolic); also in-licensing agreements with YaoPharma and 3SBio in 2025
“our acquisitions of Metsera in November 2025 and Seagen in December 2023 and our in-licensing agreements with YaoPharma and 3SBio entered into in 2025 in the obesity and cardiometabolic diseases and oncology therapeutic areas”
Seagen acquisition (oncology)
Acquired Seagen in December 2023 (oncology)
“our acquisitions of Metsera in November 2025 and Seagen in December 2023”
Business development: Seagen and Metsera
Recent business development initiatives include acquisitions of Seagen and Metsera
“See Note 2 for a discussion of our recent business development initiatives, including the acquisitions of Seagen and Metsera”
Managed care / PBM pricing pressure
MCO consolidation and PBM scrutiny increase downward pricing pressure; branded products increasingly placed on higher tiers/non-preferred status
“Since MCOs purport to seek to contain and reduce healthcare expenditures, their growing influence has increased downward pressure on drug prices, as well as negatively impacted revenues.”
R&D pipeline and therapeutic areas
R&D focused on oncology, internal medicine, vaccines, I&I; ~$500M of 2025 cost-realignment savings to be reinvested in R&D in 2026
“approximately $500 million of R&D savings achieved from our ongoing realigning our cost base program in 2025 is expected to be reinvested in R&D programs in 2026”
2026 key priorities
2026 priorities: (1) Maximize value of key transactions; (2) Deliver on critical R&D milestones; (3) Invest to maximize post-2028 growth; (4) Scale AI across our business
“Our 2026 key priorities are: 1.Maximize value of key transactions 2.Deliver on critical R&D milestones 3.Invest to maximize post-2028 growth 4.Scale AI across our business.”
Cost realignment and manufacturing optimization programs
Enterprise-wide cost realignment program (expanded 2025, AI/digital-driven SI&A savings) and multi-year Manufacturing Optimization Program (launched Q2 2024)
“In the second quarter of 2024, we announced that we launched a multi-year, multi-phased program to reduce our costs of goods sold”
September 2025 U.S. Government agreement
Sept 2025 agreement with Trump Administration: MFN-style pricing, TrumpRx.gov discounts up to 85% (avg 50%), 3-year Section 232 tariff grace period tied to U.S. manufacturing investment
“The September 2025 agreement also provides a three-year grace period during which time our products will not face Section 232 tariffs, provided the Company further invests in manufacturing in the U.S.”
EU pharmaceutical legislative initiatives
Several recently adopted or proposed EU legislative initiatives may affect the business, including the EU Pharma Package, EU HTA-R, EU Critical Medicines Act, EU Biotech Act, EU AI Act, EU Data Act, and EU Health Data Space Regulation.
“the EU Pharma Package, the EU HTA -R, the EU Critical Medicines Act, and the EU Biotech Act, as well as legislation such as the EU AI Act, EU Data Act, and the EU Health Data Space Regulation”
Cost-reduction and restructuring execution risk
Enterprise-wide cost realignment program and manufacturing optimization program may fail to deliver projected benefits; restructurings risk loss of continuity, key employees, and pipeline delays.
“our ability to realize the projected benefits of our cost-reduction and productivity initiatives, including our enterprise-wide cost realignment program and manufacturing optimization program”
Intangible assets, goodwill and IPR&D impairment risk
Significant intangible assets including IPR&D and goodwill carry impairment/write-off risk from regulatory approvals, competition, loss of market exclusivity, and adverse legal/regulatory events.
“Our consolidated balance sheet contains significant amounts of intangible assets, including IPR&D and goodwill. For IPR&D assets, the risk of failure is significant”
Tax law and regulatory change exposure (IRA, OBBBA, global minimum tax)
Results could be adversely affected by changes in laws including the IRA, the OBBBA (still subject to further guidance), and global minimum taxation requirements effective in most jurisdictions since January 1, 2024.
“the IRA, and the OBBBA, which is still subject to further guidance; the adoption of global minimum taxation requirements outside the U.S. generally effective in most jurisdictions since January 1, 2024”
IP loss and pipeline replenishment risk
Loss/expiration/invalidation of IP rights, patent litigation settlements, and licensing expirations can materially adversely affect revenues
“The loss, expiration or invalidation of intellectual property rights, patent litigation settlements and judgments, and the expiration of co-promotion and licensing rights can have a material adverse effect on our revenues.”
Managed care / PBM pricing pressure
U.S. MCO/PBM consolidation and cost-containment (rebates, formulary exclusion, prior authorization, IRA-driven pressure) may erode pricing and access
“The negotiating power of MCOs, PBMs and other private third-party payors has increased due to consolidation, and they, along with state and federal governments, increasingly employ tools to control costs”
Equity investment and pension plan volatility
Changes in fair value of equity investments increase income volatility; pension and postretirement plans are exposed to investment returns and discount rate changes.
“Our pension and postretirement plans are subject to volatility from changes in the fair value of equity investments and other investment risk in the assets funding these plans, as well as changes in the appropriate discount rates”
Tariff and trade policy exposure
New tariffs or trade/foreign policy changes could materially adversely affect business, earnings, cash flow, liquidity and financial guidance; impacts depend on scope, duration, and retaliatory tariffs.
“issued or future executive orders or other new or changes in laws, regulations or policy regarding tariffs or other trade or foreign policy, could have a material adverse effect on our business, earnings, cash flow, liquidity and financial guidance”
Competition including from China; MFN/Trump Administration pricing agreements
Rising competition including China-based entrants, generic price erosion in China, vaccine discount pressure, and voluntary U.S. pricing agreements with the Trump Administration
“we are facing an increasing number of potential competitors worldwide, including from China, that have expanded R&D capabilities.”
Government cost-cutting and data transfer restrictions
Government cost-cutting measures may impact regulatory review capacity; restrictions on data security, localization and cross-border data transfers could affect operations.
“government cost-cutting measures and related impacts on, among other matters, government staffing, resources and ability to timely review and process regulatory or other submissions; restrictions related to certain data transfers”
Customer demand shift toward sustainability / Net Zero expectations
Ability to compete could be affected by changing customer preferences, such as demand for companies to establish Net Zero targets or offer more sustainable products; perceived failure risks brand damage and reduced demand.
“changing customer preferences and requirements, such as demand for companies to establish Net Zero targets or offer more sustainable products”
Eliquis alone accounted for 13% of Total revenues in 2025 among the 12 products >$1B comprising 65% of revenues.
“Eliquis accounted for 13% of Total revenues in 2025.”
IRA pricing plus payor consolidation expected to increase pricing pressure as IRA prices become public; payors may seek larger rebates.
“as the IRA prices become publicly available, we may face greater pricing pressure from third-party payors, including insurers and PBMs”
U.S. MCO/PBM consolidation and cost-containment tools (rebates, formulary placement, utilization management) directly affect pricing and access for Pfizer products.
“The negotiating power of MCOs, PBMs and other private third-party payors has increased due to consolidation”
MCO consolidation and PBM formulary/tiering decisions increase downward pressure on drug prices and negatively impact revenues.
“their growing influence has increased downward pressure on drug prices, as well as negatively impacted revenues.”
Changes to the IRA are explicitly cited as a law whose change could adversely affect future results.
“new or changes in accounting standards, tariffs, tax laws and regulations internationally and in the U.S., including, without limitation, the IRA, and the OBBBA”
September 2025 U.S. Government agreement provides a three-year grace period from Section 232 tariffs conditional on further U.S. manufacturing investment.
“The September 2025 agreement also provides a three-year grace period during which time our products will not face Section 232 tariffs, provided the Company further invests in manufacturing in the U.S.”
COVID-19 product revenue declines drove the 2025 revenue decrease; Comirnaty has fall/winter seasonal demand.
“The operational decrease was primarily driven by declines in COVID-19 product revenues”
Recently adopted or proposed EU legislative initiatives may affect Pfizer's EU business.
“In the EU, several recently adopted or proposed legislative initiatives may affect our business, including the EU Pharma Package, the EU HTA -R, the EU Critical Medicines Act, and the EU Biotech Act”
New or changed tariffs and retaliatory actions could materially affect business, earnings, cash flow, liquidity and financial guidance.
“potential retaliatory tariffs or other retaliatory actions imposed by other countries”
COVID-19 product revenues have decreased substantially over time and could continue to decrease.
“revenues from Comirnaty and Paxlovid have decreased substantially over time and could continue to decrease.”
Paxlovid utilization follows COVID-19 infection trends; revenues fluctuate with timing, duration and severity of infections.
“For Paxlovid, utilization is expected to follow infection trends, and revenues may fluctuate based on the timing, duration and severity of COVID-19 infections.”
Paxlovid revenues trend with COVID-19 infection rates.
“In addition, Paxlovid revenues trend with COVID-19 infection rates.”
Scaling AI across R&D, manufacturing, commercial and patient engagement is a stated 2026 priority to improve productivity and accelerate innovation.
“In addition, we are scaling AI across R&D, manufacturing, commercial and patient engagement to improve productivity and accelerate innovation.”
Alliance revenues from co-commercialization partners are a disclosed revenue stream with defined accounting treatment.
“Alliance revenues are recorded as we perform co-promotion activities for the collaboration and the collaboration partners sell the products to their customers.”
Global minimum tax requirements effective since January 1, 2024 outside the U.S. are cited as a potential adverse change to results.
“the adoption of global minimum taxation requirements outside the U.S. generally effective in most jurisdictions since January 1, 2024”
Aging global population generating increased demand for innovative medicines and vaccines is cited as a long-term growth opportunity.
“an aging global population that is generating increased demand for innovative medicines and vaccines that address patients' unmet needs”
Intense generic competition in China has caused and may cause price cuts and volume loss; China-based competitors expanding R&D capabilities.
“In China, we expect to continue to face intense competition by certain generic manufacturers, which has resulted, and may result in the future, in price cuts and volume loss of some of our products.”
Receivables are pooled by government vs non-government customer type for credit-loss reserves, indicating government payer exposure.
“customer type (high risk versus low risk and government versus non-government)”
Restructurings may cause loss of key employees and retention issues, affecting operations.
“adverse effects on employee morale, loss of key employees and/or other retention issues during transitional periods”
Geopolitical and trade negotiations could disrupt raw material supply and impact costs; mitigation includes supplier management and advanced purchasing.
“We are continuing to monitor and implement mitigation strategies to reduce any potential risk or impact including active supplier management, qualification of additional suppliers and advanced purchasing to the extent possible.”
Customer preferences for Net Zero targets and sustainable products could affect Pfizer's ability to compete and product demand.
“such as demand for companies to establish Net Zero targets or offer more sustainable products”
Foreign exchange rate changes affect reported results; 2025 revenues included $247 million favorable FX impact.
“partially offset by a favorable impact of foreign exchange of $247 million”
See which prediction-market events move PFE, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.
Free forever to follow AlphaBrain’s AI strategies. No card required.
This $25 Billion Acquisition Just Unlocked a New Era of Growth for Pfizer — and Why It's a Flawless Safe-Haven for Retirees
24/7 Wall Street • STOCK • 11/06/2026, 16:26:07
A Sizzling 6.7% Dividend Yield? 1 Under-the-Radar Reason I Am Holding Off on Pfizer Stock at $25
24/7 Wall Street • STOCK • 11/06/2026, 16:23:39
Prediction: Pfizer Stock Will Double on This Date
24/7 Wall Street • STOCK • 10/06/2026, 04:06:09
RBC Capital Upgrades Pfizer (NYSE: PFE) Amid Positive Drug Developments
Market Data • Market Data • 10/06/2026, 00:18:39
Amneal and Pfizer GLP-1 Deal: New Growth Lever?
Zacks Investment Research • STOCK • 09/06/2026, 15:20:32
Pfizer Inc. (PFE) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Seeking Alpha • STOCK • 08/06/2026, 13:48:30
Wall Street Breakfast Podcast: Pfizer Chases Monthly Edge
Seeking Alpha • STOCK • 08/06/2026, 09:04:32
US FDA approves Pfizer's bleeding disorder drug for children
Reuters • STOCK • 08/06/2026, 08:49:21
3 Dividend Stocks to Buy Hand Over Fist in June
The Motley Fool • STOCK • 07/06/2026, 03:30:00
Can Pfizer's Dividend Survive the Patent Cliff? This $10.5 Billion Cancer Bet Could Hold the Answer.
The Motley Fool • STOCK • 06/06/2026, 15:32:00
Pfizer's 6.7% Yield Looks Scary -- but the Dividend Story Is Stronger Than It Seems
The Motley Fool • STOCK • 06/06/2026, 14:15:00
Pfizer's monthly obesity shot has side-effect profile similar to Wegovy in midstage trial
Reuters • STOCK • 06/06/2026, 11:06:33